Pfizer's Xeljanz hits and misses in psoriasis study
This article was originally published in Scrip
Executive Summary
Pfizer’s pill Xeljanz treated psoriasis as effectively as Enbrel at a high dose but was shown to be inferior at a lower dose, rendering a split decision on the drug’s potential expanded use and commercial outlook.